<strong>Objectives:</strong> This study aimed to determine whether additional glycine can improve urine storage symptoms in outpatients. <strong>Methods:</strong> We recruited 50 outpatients (1...<strong>Objectives:</strong> This study aimed to determine whether additional glycine can improve urine storage symptoms in outpatients. <strong>Methods:</strong> We recruited 50 outpatients (15 females, 35 males) with an Overactive Bladder Symptom Score (OABSS) of 3 or more. Participants being treated for urine storage disorders took additional glycine for 8 weeks at a dose of 3 g twice a day. Outcome measures included blood pressure, the International Prostate Symptom Score (IPSS), OABSS, Nocturia Quality of Life (N-QOL) score, urination frequency, sleep latency, time until the first void at night, bladder pain, improvement in urinary symptoms assessed with the Global Self-Assessment (GSA), and adverse events. <strong>Results:</strong> In the OABSS, the number of nighttime voids, urgency to urinate, urgent incontinence, and total score were improved. Improvements were also found in the IPSS total score for urine storage items, blood pressure, IPSS-QOL, time to first void, bladder pain, and GSA score, but no changes were seen in the frequency of urination at night, sleep latency or N-QOL score. No adverse events were recorded. <strong>Conclusion:</strong> Oral glycine improves objective and self-assessed urine storage symptoms, blood pressure, and bladder pain.展开更多
文摘<strong>Objectives:</strong> This study aimed to determine whether additional glycine can improve urine storage symptoms in outpatients. <strong>Methods:</strong> We recruited 50 outpatients (15 females, 35 males) with an Overactive Bladder Symptom Score (OABSS) of 3 or more. Participants being treated for urine storage disorders took additional glycine for 8 weeks at a dose of 3 g twice a day. Outcome measures included blood pressure, the International Prostate Symptom Score (IPSS), OABSS, Nocturia Quality of Life (N-QOL) score, urination frequency, sleep latency, time until the first void at night, bladder pain, improvement in urinary symptoms assessed with the Global Self-Assessment (GSA), and adverse events. <strong>Results:</strong> In the OABSS, the number of nighttime voids, urgency to urinate, urgent incontinence, and total score were improved. Improvements were also found in the IPSS total score for urine storage items, blood pressure, IPSS-QOL, time to first void, bladder pain, and GSA score, but no changes were seen in the frequency of urination at night, sleep latency or N-QOL score. No adverse events were recorded. <strong>Conclusion:</strong> Oral glycine improves objective and self-assessed urine storage symptoms, blood pressure, and bladder pain.
